| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Nov 2025 | 4 Nov 2025 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve the unaudited standalone & consolidated financial results for the second quarter & half year ended September 30 2025 Please find attached Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2025 (As Per Bse Announcement dated on 11/11/2025) | ||
| Board Meeting | 13 Aug 2025 | 1 Aug 2025 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve the standalone and consolidated financial results for the quarter ended June 30 2025 Unaudited Financial Results along the limited review report from the Statutory Auditor of the Company for the quarter ended June 2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 30 May 2025 | 26 May 2025 |
| Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve the Audited (Standalone and Consolidated) Financial Results for the Quarter and Financial Year ended March 31 2025 and to consider recommendation of Final Dividend if any for the Financial Year ended March 31 2025. Board Meeting Outcome for Outcome Of Board Meeting The Board of Directors have recommended a dividend of Rs. 02.00/- (Two Rupees Only) per equity share for the Financial Year ended on 31st March, 2025. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws. Information regarding Book closure/ Record date and dividend payment date will be informed in due course of time. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. Friday 30th May, 2025, Approval of Audited Financial Results For The Fourth Quarter And Year Ended 31st March, 2025, Recommendation of Dividend, appointment of Secretarial Auditor, Appointment of Cost Auditor, Appointment of Internal Auditor,Appointment of Scrutinizer (As Per BSE Announcement Dated on 30.05.2025) | ||
| Board Meeting | 24 Mar 2025 | 24 Mar 2025 |
| Appointment of Secretarial Auditor for the financial year ended on 31/03/2025 | ||
| Board Meeting | 12 Feb 2025 | 3 Feb 2025 |
| TITAN BIOTECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve Unaudited Standalone & Consolidated Financial Results For The Quarter ended on 31st December 2024 Unaudited Financial Results for the Quarter and Nine Months ended on 31-12-2024 (As Per BSE Announcement Dated on: 12/02/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.